We are a clinical stage biopharmaceutical company pioneering immuno-neurology, a novel therapeutic approach for the treatment of neurodegenerative diseases. Our approach is based on insights into human genetics, immunology and neuroscience. Just as immuno-oncology therapies recruit the peripheral adaptive immune system to counteract tumors, our immuno-neurology therapies target immune dysfunction as a root cause of multiple pathologies that are drivers of degenerative brain disorders.
The result so far: an industry-leading portfolio of immuno-neurology programs designed to harness the brain’s immune system to fight disease that we are advancing through the clinic independently and with partners.
Data Provided by Refinitiv. Minimum 15 minutes delayed.
Data provided by Refinitiv. Minimum 15 minutes delayed.